GlassScriptPhysician profile
Aimee S Polk
NPI 1376715763
$3,876.34
in general payments reported to CMS, 2019-2025
35 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,491 · 2022: $1,294 · 2023: $881 · 2024: $209.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,091.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,090.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $824.76 | 2021-2023 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $412.81 | 2021-2023 | Repatha, Prolia, Evenity |
| Abbvie INC. | $410.26 | 2021-2024 | |
| Lilly USA, LLC | $236.15 | 2021-2023 | Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $200.06 | 2021-2023 | Jardiance, Synjardy |
| Astrazeneca Pharmaceuticals LP | $195.86 | 2021-2023 | Farxiga |
| Bausch Health US, LLC | $165.22 | 2021-2023 | Aplenzin, Wellbutrin |
| Spineart USA INC | $159.53 | 2021 | |
| Sonex Health, INC. | $150.76 | 2024 | Sx-One Microknife |
| Bayer Healthcare Pharmaceuticals INC. | $141.24 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $113.36 | 2022-2023 | |
| Astellas Pharma US INC | $98.93 | 2022-2024 | Veozah |
| Abbott Laboratories | $94.59 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $69.68 | 2021-2022 | |
| Ibsa Pharma INC. | $68.08 | 2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $62.81 | 2021-2022 | |
| Medtronic, INC. | $47.90 | 2023 | Intellis Adaptivestim |
| Amarin Pharma, INC. | $43.39 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.24 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $42.93 | 2021 | |
| Pfizer INC. | $38.70 | 2021 | |
| Esperion Therapeutics, INC. | $29.62 | 2021 | |
| Janssen Pharmaceuticals, INC | $26.21 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $21.67 | 2022 | |
| Glaxosmithkline, LLC. | $20.78 | 2023 | Arexvy |
| Sumitomo Pharma America, INC. | $20.54 | 2023 | Gemtesa |
| Biohaven Pharmaceuticals, INC. | $19.34 | 2021 | |
| Daiichi Sankyo INC. | $17.88 | 2021 | |
| Exact Sciences Corporation | $17.03 | 2023 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $16.82 | 2021 | |
| Genentech USA, INC. | $15.72 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $12.97 | 2023 | Evkeeza |
| Biohaven Pharmaceutical Holding Company LTD. | $12.77 | 2022 | |
| Seqirus USA INC | $12.77 | 2021 | |
| Currax Pharmaceuticals LLC | $11.96 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aimee Polk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.